Policy & Regulation
XNK Therapeutics announces presentation at DNB Nordic Healthcare Conference in Oslo
5 December 2023 -

XNK Therapeutics AB, a Sweden-based clinical stage immunotherapy company that is focused on bringing new and more effective treatments to cancer patients, announced on Monday that Johan Liwing, CEO, will make a presentation at the DNB Nordic Healthcare Conference in Oslo, Norway, on 14 December at 10:15am CET.

This presentation will be followed by a short Q&A session, moderated by a DNB analyst.

The company is developing autologous NK cell-based cell therapy with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumour indications. Its most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma.

Login
Username:

Password: